image stringlengths 20 66 | question stringclasses 16
values | answer stringlengths 3 10.7k |
|---|---|---|
PMC2394303_fig2_23106.jpg | What is being portrayed in this visual content? | Increased apoptosis leading to depletion of TILs in FasL-expressing nests of colonic adenocarcinomas. A–F, FasL-specific immunohistochemical staining (brown) allowed identification of (A) FasL-expressing and (B) FasL-negative tumour nests in close proximity within individual colonic adenocarcinomas. On a consecutive tu... |
PMC2394303_fig2_23107.jpg | What is the focal point of this photograph? | Increased apoptosis leading to depletion of TILs in FasL-expressing nests of colonic adenocarcinomas. A–F, FasL-specific immunohistochemical staining (brown) allowed identification of (A) FasL-expressing and (B) FasL-negative tumour nests in close proximity within individual colonic adenocarcinomas. On a consecutive tu... |
PMC2394303_fig2_23109.jpg | What key item or scene is captured in this photo? | Increased apoptosis leading to depletion of TILs in FasL-expressing nests of colonic adenocarcinomas. A–F, FasL-specific immunohistochemical staining (brown) allowed identification of (A) FasL-expressing and (B) FasL-negative tumour nests in close proximity within individual colonic adenocarcinomas. On a consecutive tu... |
PMC2394303_fig4_23100.jpg | What is shown in this image? | FasL expression by colonic tumour cells does not mediate neutrophil recruitment, irrespective of TGF-β1 expression. (A–F), FasL-expressing tumour cell nests (brown) were identified by immunohistochemistry (A and B). On a consecutive tumour section, TGF-β1-specific immunoperoxidase staining (brown) allowed the TGF-β1 st... |
PMC2394303_fig4_23101.jpg | What can you see in this picture? | FasL expression by colonic tumour cells does not mediate neutrophil recruitment, irrespective of TGF-β1 expression. (A–F), FasL-expressing tumour cell nests (brown) were identified by immunohistochemistry (A and B). On a consecutive tumour section, TGF-β1-specific immunoperoxidase staining (brown) allowed the TGF-β1 st... |
PMC2394303_fig4_23103.jpg | What key item or scene is captured in this photo? | FasL expression by colonic tumour cells does not mediate neutrophil recruitment, irrespective of TGF-β1 expression. (A–F), FasL-expressing tumour cell nests (brown) were identified by immunohistochemistry (A and B). On a consecutive tumour section, TGF-β1-specific immunoperoxidase staining (brown) allowed the TGF-β1 st... |
PMC2394303_fig4_23099.jpg | What does this image primarily show? | FasL expression by colonic tumour cells does not mediate neutrophil recruitment, irrespective of TGF-β1 expression. (A–F), FasL-expressing tumour cell nests (brown) were identified by immunohistochemistry (A and B). On a consecutive tumour section, TGF-β1-specific immunoperoxidase staining (brown) allowed the TGF-β1 st... |
PMC2394303_fig4_23102.jpg | What object or scene is depicted here? | FasL expression by colonic tumour cells does not mediate neutrophil recruitment, irrespective of TGF-β1 expression. (A–F), FasL-expressing tumour cell nests (brown) were identified by immunohistochemistry (A and B). On a consecutive tumour section, TGF-β1-specific immunoperoxidase staining (brown) allowed the TGF-β1 st... |
PMC2394303_fig4_23104.jpg | What is the central feature of this picture? | FasL expression by colonic tumour cells does not mediate neutrophil recruitment, irrespective of TGF-β1 expression. (A–F), FasL-expressing tumour cell nests (brown) were identified by immunohistochemistry (A and B). On a consecutive tumour section, TGF-β1-specific immunoperoxidase staining (brown) allowed the TGF-β1 st... |
PMC2394324_fig2_23116.jpg | What is shown in this image? | Computed tomography of Case 3 shows that, although the size of the low density area did not change, the contrast enhanced lesion was decreased. Computed tomography contrast enhanced images before (A) and after (B) vaccination. Magnetic resonance imaging of Case 6 shows that the contrast enhanced lesion was decreased af... |
PMC2394324_fig2_23114.jpg | What is the focal point of this photograph? | Computed tomography of Case 3 shows that, although the size of the low density area did not change, the contrast enhanced lesion was decreased. Computed tomography contrast enhanced images before (A) and after (B) vaccination. Magnetic resonance imaging of Case 6 shows that the contrast enhanced lesion was decreased af... |
PMC2394340_fig1_23122.jpg | What is being portrayed in this visual content? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23128.jpg | What is shown in this image? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23119.jpg | Describe the main subject of this image. | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23117.jpg | What is the main focus of this visual representation? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23121.jpg | What is shown in this image? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23118.jpg | What is the principal component of this image? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23124.jpg | What is being portrayed in this visual content? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23127.jpg | What is the focal point of this photograph? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23129.jpg | What object or scene is depicted here? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23126.jpg | What is the focal point of this photograph? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23125.jpg | What's the most prominent thing you notice in this picture? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394340_fig1_23123.jpg | What key item or scene is captured in this photo? | RNF11 protein expression in tumour tissues. (A) TMA sections stained with anti-RNF11 antibody and anti-RNF11 antibody preincubated with synthetic peptide used for immunisation (magnification × 40). (B) Representative examples of RNF11-positive tumour tissues from eight different histologies as indicated on top of the e... |
PMC2394367_fig1_23130.jpg | What is shown in this image? | A prostate cancer tumour with AR gene amplification is shown. AR amplification in prostate cancer nuclei (stained with DAPI, blue) showing increased copies of both AR (red) and chromosome X (green). Magnification × 1000. |
PMC2394367_fig2_23131.jpg | Can you identify the primary element in this image? | A prostate cancer tumour that expresses AR protein is shown. AR protein expression is coloured brown and is present in the tumour cell nuclei. Magnification × 400. |
PMC2394372_fig5_23137.jpg | Can you identify the primary element in this image? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23136.jpg | What can you see in this picture? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23139.jpg | What object or scene is depicted here? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23132.jpg | Can you identify the primary element in this image? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23133.jpg | What key item or scene is captured in this photo? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23134.jpg | Can you identify the primary element in this image? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23143.jpg | What is being portrayed in this visual content? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23138.jpg | What is the principal component of this image? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23145.jpg | Can you identify the primary element in this image? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23135.jpg | What is the central feature of this picture? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394372_fig5_23141.jpg | What is the central feature of this picture? | Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M, Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C, G, K, O, S), and Masson's trichro... |
PMC2394374_fig2_23156.jpg | What is the main focus of this visual representation? | Cellular expression of SOCS-1–3 and CIS mRNA in normal breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast carcinomas, evidenced by the presence of bright silver grains on emulsion-coated sections. On sections of normal breast tissue, basal levels of SOCS-1 (C) and CIS (D) were detected in normal epithelia... |
PMC2394374_fig2_23150.jpg | What does this image primarily show? | Cellular expression of SOCS-1–3 and CIS mRNA in normal breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast carcinomas, evidenced by the presence of bright silver grains on emulsion-coated sections. On sections of normal breast tissue, basal levels of SOCS-1 (C) and CIS (D) were detected in normal epithelia... |
PMC2394374_fig2_23152.jpg | What is shown in this image? | Cellular expression of SOCS-1–3 and CIS mRNA in normal breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast carcinomas, evidenced by the presence of bright silver grains on emulsion-coated sections. On sections of normal breast tissue, basal levels of SOCS-1 (C) and CIS (D) were detected in normal epithelia... |
PMC2394374_fig2_23148.jpg | Describe the main subject of this image. | Cellular expression of SOCS-1–3 and CIS mRNA in normal breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast carcinomas, evidenced by the presence of bright silver grains on emulsion-coated sections. On sections of normal breast tissue, basal levels of SOCS-1 (C) and CIS (D) were detected in normal epithelia... |
PMC2394374_fig2_23147.jpg | What object or scene is depicted here? | Cellular expression of SOCS-1–3 and CIS mRNA in normal breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast carcinomas, evidenced by the presence of bright silver grains on emulsion-coated sections. On sections of normal breast tissue, basal levels of SOCS-1 (C) and CIS (D) were detected in normal epithelia... |
PMC2394374_fig2_23151.jpg | What is the dominant medical problem in this image? | Cellular expression of SOCS-1–3 and CIS mRNA in normal breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast carcinomas, evidenced by the presence of bright silver grains on emulsion-coated sections. On sections of normal breast tissue, basal levels of SOCS-1 (C) and CIS (D) were detected in normal epithelia... |
PMC2394374_fig2_23154.jpg | What stands out most in this visual? | Cellular expression of SOCS-1–3 and CIS mRNA in normal breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast carcinomas, evidenced by the presence of bright silver grains on emulsion-coated sections. On sections of normal breast tissue, basal levels of SOCS-1 (C) and CIS (D) were detected in normal epithelia... |
PMC2394374_fig2_23155.jpg | Can you identify the primary element in this image? | Cellular expression of SOCS-1–3 and CIS mRNA in normal breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast carcinomas, evidenced by the presence of bright silver grains on emulsion-coated sections. On sections of normal breast tissue, basal levels of SOCS-1 (C) and CIS (D) were detected in normal epithelia... |
PMC2394374_fig2_23153.jpg | Can you identify the primary element in this image? | Cellular expression of SOCS-1–3 and CIS mRNA in normal breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast carcinomas, evidenced by the presence of bright silver grains on emulsion-coated sections. On sections of normal breast tissue, basal levels of SOCS-1 (C) and CIS (D) were detected in normal epithelia... |
PMC2394385_fig1_23168.jpg | What is being portrayed in this visual content? | Case 1, neoadjuvant imatinib treatment. Positron-emission tomography examinations before (A), after 3 weeks (B), and after 12 weeks (C) of imatinib treatment. The increased uptake of the tracer [18F] fluorodeoxyglucose that was seen in a huge abdominal tumour before treatment cannot be detected at PET examinations afte... |
PMC2394385_fig1_23170.jpg | What is the focal point of this photograph? | Case 1, neoadjuvant imatinib treatment. Positron-emission tomography examinations before (A), after 3 weeks (B), and after 12 weeks (C) of imatinib treatment. The increased uptake of the tracer [18F] fluorodeoxyglucose that was seen in a huge abdominal tumour before treatment cannot be detected at PET examinations afte... |
PMC2394385_fig1_23171.jpg | What is the central feature of this picture? | Case 1, neoadjuvant imatinib treatment. Positron-emission tomography examinations before (A), after 3 weeks (B), and after 12 weeks (C) of imatinib treatment. The increased uptake of the tracer [18F] fluorodeoxyglucose that was seen in a huge abdominal tumour before treatment cannot be detected at PET examinations afte... |
PMC2394385_fig1_23165.jpg | What can you see in this picture? | Case 1, neoadjuvant imatinib treatment. Positron-emission tomography examinations before (A), after 3 weeks (B), and after 12 weeks (C) of imatinib treatment. The increased uptake of the tracer [18F] fluorodeoxyglucose that was seen in a huge abdominal tumour before treatment cannot be detected at PET examinations afte... |
PMC2394385_fig1_23173.jpg | What is the dominant medical problem in this image? | Case 1, neoadjuvant imatinib treatment. Positron-emission tomography examinations before (A), after 3 weeks (B), and after 12 weeks (C) of imatinib treatment. The increased uptake of the tracer [18F] fluorodeoxyglucose that was seen in a huge abdominal tumour before treatment cannot be detected at PET examinations afte... |
PMC2394385_fig1_23172.jpg | What does this image primarily show? | Case 1, neoadjuvant imatinib treatment. Positron-emission tomography examinations before (A), after 3 weeks (B), and after 12 weeks (C) of imatinib treatment. The increased uptake of the tracer [18F] fluorodeoxyglucose that was seen in a huge abdominal tumour before treatment cannot be detected at PET examinations afte... |
PMC2394385_fig2_23159.jpg | Describe the main subject of this image. | Case 1, neoadjuvant imatinib treatment. Pretreatment core needle biopsies of a huge abdominal tumour and liver metastases showing characteristic features of a malignant spindled and epithelioid GIST (A) that is immunoreactive for CD117 (B) and MIB1 (Ki67 proliferative index=10%) (C). After 3 months of imatinib treatmen... |
PMC2394385_fig2_23163.jpg | Can you identify the primary element in this image? | Case 1, neoadjuvant imatinib treatment. Pretreatment core needle biopsies of a huge abdominal tumour and liver metastases showing characteristic features of a malignant spindled and epithelioid GIST (A) that is immunoreactive for CD117 (B) and MIB1 (Ki67 proliferative index=10%) (C). After 3 months of imatinib treatmen... |
PMC2394385_fig2_23164.jpg | Can you identify the primary element in this image? | Case 1, neoadjuvant imatinib treatment. Pretreatment core needle biopsies of a huge abdominal tumour and liver metastases showing characteristic features of a malignant spindled and epithelioid GIST (A) that is immunoreactive for CD117 (B) and MIB1 (Ki67 proliferative index=10%) (C). After 3 months of imatinib treatmen... |
PMC2394385_fig2_23162.jpg | What is shown in this image? | Case 1, neoadjuvant imatinib treatment. Pretreatment core needle biopsies of a huge abdominal tumour and liver metastases showing characteristic features of a malignant spindled and epithelioid GIST (A) that is immunoreactive for CD117 (B) and MIB1 (Ki67 proliferative index=10%) (C). After 3 months of imatinib treatmen... |
PMC2394385_fig2_23161.jpg | What is the main focus of this visual representation? | Case 1, neoadjuvant imatinib treatment. Pretreatment core needle biopsies of a huge abdominal tumour and liver metastases showing characteristic features of a malignant spindled and epithelioid GIST (A) that is immunoreactive for CD117 (B) and MIB1 (Ki67 proliferative index=10%) (C). After 3 months of imatinib treatmen... |
PMC2394385_fig2_23160.jpg | What key item or scene is captured in this photo? | Case 1, neoadjuvant imatinib treatment. Pretreatment core needle biopsies of a huge abdominal tumour and liver metastases showing characteristic features of a malignant spindled and epithelioid GIST (A) that is immunoreactive for CD117 (B) and MIB1 (Ki67 proliferative index=10%) (C). After 3 months of imatinib treatmen... |
PMC2394393_fig1_23176.jpg | What object or scene is depicted here? | E-cadherin expression in normal oral epithelium. (A) Negative control, original magnification × 170; (B) E-cadherin is detected mainly on the cell membrane of the basal layer to the spinosum layer, original magnification × 170. |
PMC2394393_fig1_23177.jpg | Describe the main subject of this image. | E-cadherin expression in normal oral epithelium. (A) Negative control, original magnification × 170; (B) E-cadherin is detected mainly on the cell membrane of the basal layer to the spinosum layer, original magnification × 170. |
PMC2394393_fig2_23175.jpg | What key item or scene is captured in this photo? | E-cadherin expression in oral squamous cell carcinoma. (A) An oral squamous cell carcinoma shows preserved E-cadherin expression, original magnification × 170; (B) An oral squamous cell carcinoma shows reduced E-cadherin expression, original magnification × 170. |
PMC2394393_fig3_23178.jpg | What key item or scene is captured in this photo? | α-catenin expression in oral squamous cell carcinoma. (A) An oral squamous cell carcinoma shows preserved α-catenin expression, original magnification × 170; (B) An oral squamous cell carcinoma shows reduced α-catenin expression, original magnification × 170. |
PMC2394393_fig3_23179.jpg | Describe the main subject of this image. | α-catenin expression in oral squamous cell carcinoma. (A) An oral squamous cell carcinoma shows preserved α-catenin expression, original magnification × 170; (B) An oral squamous cell carcinoma shows reduced α-catenin expression, original magnification × 170. |
PMC2394393_fig3_23180.jpg | What stands out most in this visual? | α-catenin expression in oral squamous cell carcinoma. (A) An oral squamous cell carcinoma shows preserved α-catenin expression, original magnification × 170; (B) An oral squamous cell carcinoma shows reduced α-catenin expression, original magnification × 170. |
PMC2394393_fig4_23181.jpg | Describe the main subject of this image. | β-catenin expression in oral squamous cell carcinoma. (A) An oral squamous cell carcinoma shows preserved β-catenin expression, original magnification × 170; (B) An oral squamous cell carcinoma shows reduced β-catenin expression, original magnification × 170. |
PMC2394408_fig2_23183.jpg | What is the dominant medical problem in this image? | Immunohistochestochemical detection of cancer cells in the axillary lymph node. Photomicrograph of CK19-positive cancer cells in lymph node (magnification × 400). |
PMC2394422_fig1_23184.jpg | What stands out most in this visual? | Histology of biopsies taken after the completion of therapy. Complete necrosis of the tumour tissue and a mainly peritumoral lymphocytic infiltrate (A) haematoxylin and eosin; original magnification × 40. No viable tumour cells are recognisable; necrotic tumour cells appear as cell shadows. Furthermore, monocytes and m... |
PMC2394422_fig1_23185.jpg | What can you see in this picture? | Histology of biopsies taken after the completion of therapy. Complete necrosis of the tumour tissue and a mainly peritumoral lymphocytic infiltrate (A) haematoxylin and eosin; original magnification × 40. No viable tumour cells are recognisable; necrotic tumour cells appear as cell shadows. Furthermore, monocytes and m... |
PMC2394422_fig2_23187.jpg | Can you identify the primary element in this image? | Immunoflourescence staining for Melan A/Mart-1 (green) and caspase-3 (red) detects vital and apoptotic tumour cells. Nuclei stained blue. Images were taken using a CLSM at 630-fold magnification (A). Confocal laser scanning microscopy image of the inflammatory infiltrate: CD3-positive T-lymphocytes stained blue, CD56-p... |
PMC2394422_fig2_23186.jpg | What is being portrayed in this visual content? | Immunoflourescence staining for Melan A/Mart-1 (green) and caspase-3 (red) detects vital and apoptotic tumour cells. Nuclei stained blue. Images were taken using a CLSM at 630-fold magnification (A). Confocal laser scanning microscopy image of the inflammatory infiltrate: CD3-positive T-lymphocytes stained blue, CD56-p... |
PMC2394431_fig1_23189.jpg | What object or scene is depicted here? | Sagittal single slice images through the tumour and muscle of the hind limb. Dynamic contrast-enhanced magnetic resonance imaging images were acquired before, and 2 and 10 min after, injection of the contrast agent (Gd-DTPA). The tumour rim enhanced rapidly and the core more slowly. Muscle of the hind limb is located t... |
PMC2394431_fig1_23190.jpg | What's the most prominent thing you notice in this picture? | Sagittal single slice images through the tumour and muscle of the hind limb. Dynamic contrast-enhanced magnetic resonance imaging images were acquired before, and 2 and 10 min after, injection of the contrast agent (Gd-DTPA). The tumour rim enhanced rapidly and the core more slowly. Muscle of the hind limb is located t... |
PMC2394489_fig1_23192.jpg | Can you identify the primary element in this image? | (A) Score 1. Less than 10% of the cells are stained by anti-Glut-1 (magnification × 10). (B) Score 2. Between 10 and 50% of the cells are stained with Glut-1. Strong membranous staining is seen adjacent to an area of necosis. (magnification × 20). (C) Score 3. More than 50% of cells are stained with Glut-1 at the invas... |
PMC2394489_fig1_23193.jpg | What is the central feature of this picture? | (A) Score 1. Less than 10% of the cells are stained by anti-Glut-1 (magnification × 10). (B) Score 2. Between 10 and 50% of the cells are stained with Glut-1. Strong membranous staining is seen adjacent to an area of necosis. (magnification × 20). (C) Score 3. More than 50% of cells are stained with Glut-1 at the invas... |
PMC2394517_F2_23197.jpg | What is shown in this image? | Carcinogen-treated Ws/Ws rats developed mammary carcinomas. Panel A: whole mounts of mammary glands obtained from NMU-treated wild type and Ws/Ws rats. Only the mutant rats developed tumors while the microscopic lesions observed in the wild type mammary glands were benign lesions. Panel B: Histological sections of the ... |
PMC2394517_F2_23198.jpg | What is being portrayed in this visual content? | Carcinogen-treated Ws/Ws rats developed mammary carcinomas. Panel A: whole mounts of mammary glands obtained from NMU-treated wild type and Ws/Ws rats. Only the mutant rats developed tumors while the microscopic lesions observed in the wild type mammary glands were benign lesions. Panel B: Histological sections of the ... |
PMC2394517_F2_23194.jpg | Can you identify the primary element in this image? | Carcinogen-treated Ws/Ws rats developed mammary carcinomas. Panel A: whole mounts of mammary glands obtained from NMU-treated wild type and Ws/Ws rats. Only the mutant rats developed tumors while the microscopic lesions observed in the wild type mammary glands were benign lesions. Panel B: Histological sections of the ... |
PMC2394517_F2_23201.jpg | What is being portrayed in this visual content? | Carcinogen-treated Ws/Ws rats developed mammary carcinomas. Panel A: whole mounts of mammary glands obtained from NMU-treated wild type and Ws/Ws rats. Only the mutant rats developed tumors while the microscopic lesions observed in the wild type mammary glands were benign lesions. Panel B: Histological sections of the ... |
PMC2394530_F2_23202.jpg | What is the dominant medical problem in this image? | X-ray showing multiple soft-tissue swellings, hypotrophy of the bone, and multiple well-defined, radio-opaque lesions consistent with phleboliths. |
PMC2394531_F1_23205.jpg | What stands out most in this visual? | Axial CT scan of the abdomen, performed on 7 July 2003. Several cysts are shown in the right kidney, the largest measuring 6 cm in diameter. The outline of the right kidney was intact. The perirenal fat was seen without any discontinuity. The gall bladder contained several stones. |
PMC2394531_F1_23206.jpg | What is shown in this image? | Axial CT scan of the abdomen, performed on 7 July 2003. Several cysts are shown in the right kidney, the largest measuring 6 cm in diameter. The outline of the right kidney was intact. The perirenal fat was seen without any discontinuity. The gall bladder contained several stones. |
PMC2394531_F2_23209.jpg | What is the main focus of this visual representation? | Axial CT scan of the abdomen, performed on 5 March 2007. Cysts in upper pole of right kidney are shown, the largest measuring 7 cm. In contrast to Figure 1, there was a marked loss of fat plane between the mid-pole of the right kidney and the postero-lateral abdominal wall. |
PMC2394531_F2_23208.jpg | What key item or scene is captured in this photo? | Axial CT scan of the abdomen, performed on 5 March 2007. Cysts in upper pole of right kidney are shown, the largest measuring 7 cm. In contrast to Figure 1, there was a marked loss of fat plane between the mid-pole of the right kidney and the postero-lateral abdominal wall. |
PMC2394531_F3_23211.jpg | What is the dominant medical problem in this image? | Sagittal reconstruction of the CT scan of the abdomen, performed on 5 March 2007. Communication between the cyst in the right kidney and the exterior through a defect in the anterior abdominal wall musculature is revealed. |
PMC2394531_F3_23210.jpg | What can you see in this picture? | Sagittal reconstruction of the CT scan of the abdomen, performed on 5 March 2007. Communication between the cyst in the right kidney and the exterior through a defect in the anterior abdominal wall musculature is revealed. |
PMC2394532_F3_23204.jpg | What is the main focus of this visual representation? | X-Ray of the paraspinal and pelvic region showing calcification. |
PMC2394533_F1_23212.jpg | What is the focal point of this photograph? | Computed tomography appearance of giant splenic hemangioma and liver hemangiomatosis. Cavernous hemangioma of the spleen and multiple hepatic cavernous hemangiomas displayed in a computed tomography hypodense image after IV contrast injection and peripheral, centripetal enhancement. |
PMC2394536_F3_23218.jpg | What is shown in this image? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23215.jpg | What is the principal component of this image? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23221.jpg | What key item or scene is captured in this photo? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23224.jpg | What's the most prominent thing you notice in this picture? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23222.jpg | What stands out most in this visual? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23223.jpg | What is the dominant medical problem in this image? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23219.jpg | What can you see in this picture? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23220.jpg | What object or scene is depicted here? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23216.jpg | What is the dominant medical problem in this image? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23225.jpg | What is being portrayed in this visual content? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23217.jpg | What is the focal point of this photograph? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394536_F3_23214.jpg | What is the dominant medical problem in this image? | Lectin histochemical staining of MDA-MB-231 breast cancer cell line and ductal carcinoma in situ.A) Cytospin slides of MDA-MB-231 cells, which were grown in vitro and harvested using enzyme-free buffer. The negative control and staining with GS-I and VVA are shown. MDA-MB-231 breast cancer cell line shows cytoplasmic s... |
PMC2394572_fig4_23227.jpg | What is being portrayed in this visual content? | Ultrastructural recovery of the outer limiting membrane 1 week post AAA administration. Electron micrographs of retinal sections from PBS and AAA treated wildtype mice, sacrificed at 72 h (a, b) and 1 week (c) post intravitreal injection. (a) Normal retinal structure was observed in the PBS treated retina and continuou... |
PMC2394572_fig4_23226.jpg | What is the focal point of this photograph? | Ultrastructural recovery of the outer limiting membrane 1 week post AAA administration. Electron micrographs of retinal sections from PBS and AAA treated wildtype mice, sacrificed at 72 h (a, b) and 1 week (c) post intravitreal injection. (a) Normal retinal structure was observed in the PBS treated retina and continuou... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.